Literature DB >> 23860127

A container closure system that allows for greater recovery of radiolabeled peptide compared to the standard borosilicate glass system.

Alicia K Leece1, Pedram Heidari, Daniel L Yokell, Umar Mahmood.   

Abstract

OBJECTIVES: Often peptides used in synthesis of radiopharmaceutical PET tracers are lipophilic and adhere to the walls of container closure systems (CCS) such that costly peptide and product are not fully recoverable after synthesis occurs. This investigation compares a standard United States Pharmacopeia (USP) Type I borosilicate glass CCS to a cyclic polyolefin copolymer Crystal Zenith(®) (CZ) CCS, for (68)Ga-chloride and (68)Ga-DOTATOC ([(68)Ga] Ga-DOTA-D-Phe1-Tyr3-octreotide) retention in the reaction vial after labeling.
METHODS: (68)Gallium labeling of DOTATOC was conducted by adding (68)Ga-chloride, 2M HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) or 0.75 M sodium acetate, and 1-30 µg of DOTATOC into the CZ or glass CCS. The reaction mixture was heated for 15 min and cooled to room temperature. The crude reaction mixture was then withdrawn via syringe, for final processing. The CCS was then assayed using a dose calibrator to determine the amount of retained (68)Ga-DOTATOC. Statistical significance was assessed using an unpaired Student's t-test.
RESULTS: In all experiments (n=72) with various amounts of peptide and different buffering systems, the CZ CCS retained less activity than the glass CCS. Using 2 M HEPES and 15 µg or 30 µg of DOTATOC, the CZ CCS retained approximately 10% less of the labeled DOTATOC compared to the glass CCS (p<0.05). Utilizing either a sodium acetate or a HEPES buffering system with 15 µg or 30 µg of DOTATOC, the CZ CCS retained approximately 2.5% less of the total reaction activity compared to the glass CCS (p<0.05). Product yield was equivalent in glass and CZ CCS under the same reaction conditions. Both the CZ and glass vials showed no retention of (68)Ga-chloride.
CONCLUSION: For applications involving the labeling of peptides such as (68)Ga-DOTATOC, the CZ CCS compared to the glass CCS, results in an improved recovery of product.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (68)Ga-DOTATOC; Crystal resin closure system; Peptide adsorption; Recovery

Mesh:

Substances:

Year:  2013        PMID: 23860127      PMCID: PMC3753669          DOI: 10.1016/j.apradiso.2013.06.019

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  10 in total

1.  Evaluation of CZ-resin vials for packaging protein-based parenteral formulations.

Authors:  S S Qadry; T H Roshdy; H Char; S Del Terzo; R Tarantino; J Moschera
Journal:  Int J Pharm       Date:  2003-02-18       Impact factor: 5.875

2.  Container system for enabling commercial production of cryopreserved cell therapy products.

Authors:  Erik J Woods; Aniruddha Bagchi; W Scott Goebel; Vinod D Vilivalam; Vinod D Vilivalam
Journal:  Regen Med       Date:  2010-07       Impact factor: 3.806

Review 3.  68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals.

Authors:  Melpomeni Fani; João P André; Helmut R Maecke
Journal:  Contrast Media Mol Imaging       Date:  2008 Mar-Apr       Impact factor: 3.161

4.  Direct visualization of protein adsorption to primary containers by gold nanoparticles.

Authors:  Bruce Eu; Alex Cairns; Grace Ding; Xiaolin Cao; Zai-Qing Wen
Journal:  J Pharm Sci       Date:  2010-11-30       Impact factor: 3.534

5.  The importance of using the optimal plasticware and glassware in studies involving peptides.

Authors:  Miriam Goebel-Stengel; Andreas Stengel; Yvette Taché; Joseph R Reeve
Journal:  Anal Biochem       Date:  2011-03-09       Impact factor: 3.365

6.  Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides.

Authors:  Erik de Blois; Ho Sze Chan; Clive Naidoo; Deidre Prince; Eric P Krenning; Wouter A P Breeman
Journal:  Appl Radiat Isot       Date:  2010-11-23       Impact factor: 1.513

7.  Improvement of recovery and repeatability in liquid chromatography-mass spectrometry analysis of peptides.

Authors:  Paul M van Midwoud; Laurent Rieux; Rainer Bischoff; Elisabeth Verpoorte; Harm A G Niederländer
Journal:  J Proteome Res       Date:  2007-02       Impact factor: 4.466

8.  Processing of generator-produced 68Ga for medical application.

Authors:  Konstantin P Zhernosekov; Dimitry V Filosofov; Richard P Baum; Peter Aschoff; Heiner Bihl; Anatoli A Razbash; Markus Jahn; Mark Jennewein; Frank Rösch
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

Review 9.  The synthesis and chelation chemistry of DOTA-peptide conjugates.

Authors:  Luis M De León-Rodríguez; Zoltan Kovacs
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

10.  A fully automated synthesis for the preparation of 68Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner
Journal:  Nucl Med Commun       Date:  2007-11       Impact factor: 1.690

  10 in total
  3 in total

1.  Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use.

Authors:  Pedram Heidari; Alicia Szretter; Laura E Rushford; Maria Stevens; Lee Collier; Judit Sore; Jacob Hooker; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-07-06

2.  Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.

Authors:  Pedram Heidari; Anchisa Kunawudhi; Jordi Martinez-Quintanilla; Alicia Szretter; Khalid Shah; Umar Mahmood
Journal:  Theranostics       Date:  2018-05-23       Impact factor: 11.556

3.  Evaluation of Crystal Zenith Microtiter Plates for High-Throughput Formulation Screening.

Authors:  J Alaina Floyd; Jeremy M Shaver; Alison J Gillespie; Unjy Park; Richard S Rogers; Nancy S Nightlinger; Yuko Ogata; Jeffrey J James; Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2019-10-25       Impact factor: 3.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.